IND7 Insights into Adbry® and a Patient Spotlight: An Update on the Efficacy and Safety of the Only Biologic Targeting IL-13 for Moderate-to-Severe Atopic Dermatitis
Sat, Mar 9, 10:30 AM - 11:15 AM
Exhibit Hall - Theater 1
Focus Session
DESCRIPTION
A patient-focused program where two leading dermatologists review the latest efficacy and safety data of Adbry® and feature a real-world patient to discuss insights into their treatment experience.
Presented: By LEO